|Videos|February 24, 2022

How to talk with parents about the recent Pfizer/BioNTech news for the youngest kids

Author(s)Miranda Hester

Editor-in-chief Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, discusses how to help parents who are worried or nervous about the delay in the expansion of the Pfizer/BioNTech vaccine to children aged 6 months to younger than 4 years.

Editor-in-chief Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, discusses how to help parents who are worried or nervous about the delay in the expansion of the Pfizer/BioNTech vaccine to children aged 6 months to younger than 4 years.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

Tezepelumab meets co-primary and secondary endpoints in phase 3 eosinophilic esophagitis trial | Image Credit: © Yurii Kibalnik - stock.adobe.com

Tezepelumab meets co-primary and secondary endpoints in phase 3 eosinophilic esophagitis trial

ByMorgan Ebert, Executive Editor

September 14th 2026

FDA approves apitegromab-mstn as first muscle-targeted therapy for spinal muscular atrophy

FDA approves apitegromab-mstn as first muscle-targeted therapy for spinal muscular atrophy

ByMorgan Ebert, Executive Editor

September 14th 2026

XOCOVA offers new post-exposure COVID-19 prevention option for adolescents

XOCOVA offers new post-exposure COVID-19 prevention option for adolescents

ByCharles Vega, MD, FAAFP

September 10th 2026

Navepegritide shows early safety and growth signals in infants with achondroplasia | Image Credit: © Gorodenkoff - stock.adobe.com.

Navepegritide shows early safety and growth signals in infants with achondroplasia

ByMorgan Ebert, Executive Editor

September 10th 2026

Vosoritide improves growth velocity in children with hypochondroplasia, phase 3 trial shows | Image Credit: © HockleyM2/peopleimages.com - stock.adobe.com.

Vosoritide improves growth velocity in children with hypochondroplasia, phase 3 trial shows

ByMorgan Ebert, Executive Editor

September 9th 2026

Latest CME

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Jordan Axelrad, MD, MPH, FACG, FCCF; Jessica R. Allegretti, MD, MPH; Florian Rieder, MD

Trending on Contemporary Pediatrics

FAQ: What's new in COVID-19, RSV, and flu guidance?

Teen sports supplements: What to recommend, use with caution, and avoid

XOCOVA offers new post-exposure COVID-19 prevention option for adolescents

FDA approves apitegromab-mstn as first muscle-targeted therapy for spinal muscular atrophy

FDA approves leniolisib for children aged 4 to 11 with APDS